Form 8-K - Current report:
SEC Accession No. 0001193125-26-332742
Filing Date
2026-08-04
Accepted
2026-08-04 16:03:07
Documents
16
Period of Report
2026-07-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d133274d8k.htm   iXBRL 8-K 33578
2 EX-5.1 d133274dex51.htm EX-5.1 11457
3 EX-10.1 d133274dex101.htm EX-10.1 31422
4 EX-10.2 d133274dex102.htm EX-10.2 55294
8 GRAPHIC g133274g0804031743525.jpg GRAPHIC 3126
9 GRAPHIC g133274g0804031744665.jpg GRAPHIC 2354
  Complete submission text file 0001193125-26-332742.txt   283441

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20260731.xsd EX-101.SCH 3194
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20260731_lab.xml EX-101.LAB 17232
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20260731_pre.xml EX-101.PRE 10821
19 EXTRACTED XBRL INSTANCE DOCUMENT d133274d8k_htm.xml XML 3507
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 261238421
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)